Krishna Menon, PhD, VMD, MRCS
Chief Regulatory Officer

Dr. Menon was originally trained as a veterinary surgeon. He was Director of Agriculture for Cayman Islands, in the British Caribbean during 1978-1981. Thereafter he came to the Dana Farber Cancer Research Institute and obtained a PhD in Pharmacology in 1984 from Harvard University. He worked under the direction of Nobel Laureate Dr. Tom Frye. His PhD work involved anti-folate therapy of various cancers, which has led to the extremely important drugs, methotrexate and recently, the blockbuster Alimta. He was Research Scientist at Dana Farber between 1985 to 1990. He was Senior Research Scientist, In Vivo Research (Cancer), at Bayer Pharmaceuticals (Miles Laboratories) during 1991-1993. He had his own veterinary oncology and drug development consultancy practice during 1994. Thereafter, he was Group Leader, Cancer In Vivo Research and Clinical Development, at Eli Lilly and Company during 1995-2001. He was responsible for the development of the anticancer drugs Cryptophycin and the blockbusters, Gemzar and Alimta. He also helped developed another seven compounds at Lilly which are in late clinical phases at present. He has also contributed to the development of an anti-infective drug by Nexus Pharmaceuticals.